QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ABEO

QT68Abeona Therapeutics Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
5.77
+0.12+2.12%
OverviewShort InterestFilings
ABEOQT68Abeona Therapeutics Inc.·NASDAQ
OverviewShort InterestFilings
5.77+2.12%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E4.84EPS (ttm)
1.17
Insider Own-
Shs Outstand57.00M
Perf Week4.34%
Market Cap322.02MForward P/E-EPS next Y-0.06Insider Trans-0.77%Shs Float-Perf Month12.70%
Enterprise Value283.82MPEG0.02EPS next Q-0.23Inst Own-Short Float-Perf Quarter27.09%
Income66.56MP/S22.15EPS this Y-161.78%Inst Trans-Short Ratio-Perf Half Y15.40%
Sales14.54MP/B2.21EPS next Y90.99%ROA33.32%Short Interest-Perf YTD9.49%
Book/sh2.54P/C-EPS next 5Y-ROE41.40%52W High7.54 -23.47%Perf Year-3.83%
Cash/sh2.95P/FCF-EPS past 3/5Y-ROIC-50.87%52W Low4.00 44.25%Perf 3Y-
Dividend Est.-EV/EBITDA3.87Sales past 3/5Y81.71% -9.71%Gross Margin51.93%Volatility2.61% 2.74%Perf 5Y-
Dividend TTM-EV/Sales19.52EPS Y/Y TTM162.58%Oper. Margin-637.92%ATR (14)0.24Perf 10Y-
Dividend Ex-DateMar 31, 2000Quick Ratio5.70Sales Y/Y TTM-Profit Margin454.86%RSI (14)57.47Recom2.33
Dividend Gr. 3/5Y-Current Ratio5.89EPS Q/Q-25.00%SMA203.07%Beta1.45Target Price17.00
Payout0.00%Debt/Eq0.16Sales Q/Q-SMA504.36%Rel Volume1.02Prev Close5.65
Employees136LT Debt/Eq0.08EarningsAug 13SMA20010.18%Avg Volume1.09MPrice5.77
IPO DateSep 19, 1980Option/ShortYes / YesEPS/Sales Surpr.9.09% 80.00%Net Debt/EBITDA-0.52Volume1,111,173Change2.12%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-17-26ReiteratedStifel Nicolaus$20 → $17
May-16-25ReiteratedStifel Nicolaus$21 → $20
Mar-05-25InitiatedOppenheimerOutperform$16
Nov-14-22ReiteratedLeerink Partners$6.00
Nov-30-21DowngradeSVB LeerinkOutperform → Market Perform
Nov-11-20UpgradeCantor FitzgeraldNeutral → Overweight
Aug-15-19DowngradeMaxim GroupBuy → Hold
Aug-12-19DowngradeCantor FitzgeraldOverweight → Neutral
Jul-26-19DowngradeMizuhoBuy → Neutral
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue604
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A232
Gross Profit4-32
Selling, General and Administrative Excl. Other653019
Research and Development273431
Other Operating Expense2-3-1
Operating Income-89-64-47
Interest Expense440
Unusual Expense
———
Non-Operating Income (Expense)-164-57
Net Income Before Taxes71-64-54
Income Taxes
000
Consolidated Net Income71-64-54
Net Income From Continuing Operations71-64-54
Net Income71-64-54
EPS (Recurring)1.34-1.55-2.53
EPS (Basic, Before Extraordinaries)1.34-1.55-2.53
EPS (Diluted)1.01-1.55-2.53
EBITDA79-57-51
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio5.22——
Price To Sales Ratio46.55——
Gross Margin66.67—50.00
Operating Margin-1,483.33—-1,175.00
Net Margin1,183.33—-1,350.00
Shares Outstanding534121
Market Capitalization279——
Operating Lease Expense
———
Insider Trading Volume
$6.16$5.74$5.32$4.91$4.49● Close Price0.00K228.42K456.85K685.27K913.69KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Silverstein Christine BerniDirectorJun 15 '26Sale5.7118,160103,695119,562Jun 15 12:00 AM
Seshadri VishwasChief Executive OfficerJun 09 '26Sale5.3031,916169,2891,374,079Jun 09 12:00 AM
O'Malley Brendan M.SVP, Chief Legal OfficerJun 09 '26Sale5.306,30533,443440,003Jun 09 12:00 AM
Vazzano Joseph WalterChief Financial OfficerJun 09 '26Sale5.3639,067209,476518,437Jun 09 12:00 AM
Vasanthavada MadhavChief Commercial OfficerJun 09 '26Sale5.305,45028,908303,451Jun 09 12:00 AM
Vasanthavada MadhavChief Commercial OfficerJun 08 '26Sale5.434,17022,641308,901Jun 09 12:00 AM
Vazzano Joseph WalterChief Financial OfficerJun 08 '26Sale5.4310,27155,766557,504Jun 09 12:00 AM
O'Malley Brendan M.SVP, Chief Legal OfficerJun 08 '26Sale5.434,82626,203446,308Jun 09 12:00 AM
Seshadri VishwasChief Executive OfficerJun 08 '26Sale5.4324,428132,6321,405,995Jun 09 12:00 AM
Alvino MarkDirectorMay 22 '26Sale5.466,50035,46377,565May 22 12:00 AM
Crombez EricDirectorMay 15 '26Sale5.5326,143144,63637,313May 15 12:00 AM
Vasanthavada MadhavChief Commercial OfficerMay 11 '26Sale5.965,54833,073313,071May 11 12:00 AM
Seshadri VishwasChief Executive OfficerMar 31 '26Sale4.3829,985131,4811,430,423Mar 31 12:00 AM
Vazzano Joseph WalterChief Financial OfficerMar 16 '26Sale4.767853,737567,775Mar 16 12:00 AM
Silverstein Christine BerniDirectorFeb 02 '26Sale5.0920,070102,168137,722Feb 04 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR